SOLICITATION NOTICE
B -- Bio-Rad Bio-Plex Assays
- Notice Date
- 2/2/2016
- Notice Type
- Presolicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(HG)-2016-077-DM
- Archive Date
- 2/22/2016
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute, (NHGRI), intends to negotiate and award a purchase order on a non-competitive sole source basis to Bio-Rad Laboratories, 2000 Alfred Nobel Drive, Hercules, California 94547-1804. (BRAND-NAME: BIO-RAD LABORATORIES: Bio-Plex Assays) Procurement: 1. Bio-Plex Pro Human Diabetes 10-plex, Catalog Number: 171A7001M, Quantity: Fifty (50); 2. Bio-Plex Pro Hu Diab Adipsin/nectin 2plx, Catalog Number: 171A7002M, Quantity: Fifty (50); 3. Bio-Plex Data Pro Plus Software, Catalog Number: 171001523 Background: The National Institute of Health (NIH) is the nation's leading medical research agency and the primary Federal agency seeking fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Human Genome Research Institute (NHGRI), mission has expanded to encompass a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and disease. A critical part of the NHGRI mission continues to be the study of the ethical, legal and social implications (ELSI) of genome research. The mission of the Center for Research on Genomics and Global Health (CRGGH) is to advance research into the role of culture, lifestyle, genetics and genomics in health disparities. CRGGH will develop genetic epidemiology models and conduct population genetics research that explores the patterns and determinants of common complex diseases, such as Type 2 Diabetes, hypertension and obesity in the US, Africa and China. CRGGH will give particular thought to ways in which scientist's document and describe the non-random pattern of human genetic variation and its link to disease risks in different populations. Purpose and Objectives: The Bio-Plex Human Diabetes kits will be used by CRGGH lab. The kits will be used to perform analysis and quantitation of different biomolecules (proteins, peptides, and nucleic acids) in a single microplate well from sample sources such as cell culture media, serum, plasma, and other matrices. Conducting whole genome analysis is a part of the CRGGH mission. The Center for Research on Genomic and Global Health (CRGGH) has ongoing large-scale genetic epidemiology studies globally. As part of these studies, the center has accrued and continues to accrue serological samples from international collaborators. CRGGH estimates that keeping this methodology will result in rapid depletion of the current samples thus limiting our potential to explore other avenues using our current resource. Conscientious of these limitations for measuring certain markers in blood products, the center using Bio-Rad's Bio-Plex 200 system that allows multiplexing assays using serum or plasma samples with volume as low as 50 ul for up to 12 different adipokines at a time. The acquisition of the Bio-Plex array system from Bio-Rad allowed the center to ask research questions that were not previously investigated and open new research horizons, therefore custom Bio-Plex Assays are further needed to continue to the critical research performed. In continuity with CRGGH's previous research work i.e. understanding the genetic epidemiology of complex diseases in population of African descent, the present project will expand the measurement of a set of adipokines (diabetes panel) in about 4000 serum samples. To rigorously conduct this study, we must use the same analytical methods that were previously used to measure serum adipokines in existing cohorts i.e. Bio-Plex 200 system and its associated reagents and consumables (e.g. Bio-Plex Pro Human Diabetes 10-plex, Bio-Plex Pro Hu Diab Adipsin/nectin 2plx). Other Considerations: Bio-Rad Laboratories Bio-Plex Assays are being fully customized to the end-user's specifications and lot matched. Bio-Plex assays are manufactured and sold only by Bio-Rad Laboratories and used on Bio-Rad Systems. Period of Performance: 12 Months Upon Award Regulatory Authority: This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1(b) Soliciting from a single source and is not expected to exceed the simplified acquisition threshold, only one responsible source and no other supplies or services will satisfy agency requirements. Statutory Authority: This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Additional Information: Industry Classification (NAICS) Code is Industry Classification (NAICS) Code is 325414, Biological Product (except Diagnostic) Manufacturing and small business size standard is 500. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-86-2 (February 1, 2016). This requirement is under the SAT of $150,000.00. This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by January 7, 2016 and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2016-077-DM by 7:30 a.m. Eastern Time, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(HG)-2016-077-DM/listing.html)
- Place of Performance
- Address: NIH, Bethesda, Maryland, United States
- Record
- SN04007097-W 20160204/160202234248-667968ff70f238595019b6a01b5d8ea7 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |